Sarepta Therapeutics, Inc.
🏢 View company profile →123Patents
122Active
123Granted
60Portfolio score
Filing activity: May 10, 2006 → Apr 6, 2023 · 12 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8865883B2 | Multiple exon skipping compositions for DMD | Chemistry; Metallurgy | 89 | Active |
| US8501703B2 | Chimeric oligomeric compounds for modulation of splicing | Chemistry; Metallurgy | 87 | Active |
| US9416361B2 | Splice-region antisense composition and method | Chemistry; Metallurgy | 86 | Active |
| US8895722B2 | Splice-region antisense composition and method | Chemistry; Metallurgy | 84 | Active |
| US8835402B2 | Compound and method for treating myotonic dystrophy | Chemistry; Metallurgy | 78 | Active |
| US8871918B2 | Multiple exon skipping compositions for DMD | Chemistry; Metallurgy | 64 | Active |
| US9506058B2 | Compositions for treating muscular dystrophy | Chemistry; Metallurgy | 59 | Active |
| US8779128B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | Emerging Cross-Sectional Technologies | 58 | Active |
| US8741863B2 | Compound and method for treating myotonic dystrophy | Chemistry; Metallurgy | 54 | Active |
| US9447417B2 | Multiple exon skipping compositions for DMD | Chemistry; Metallurgy | 52 | Active |
| US9434948B2 | Multiple exon skipping compositions for DMD | Chemistry; Metallurgy | 51 | Active |
| US8877725B2 | Peptide conjugated, inosine-substituted antisense oligomer compound and method | Chemistry; Metallurgy | 48 | Active |
| US8536147B2 | Antibacterial antisense oligonucleotide and method | Chemistry; Metallurgy | 47 | Active |
| US8785410B2 | Antisense composition and method for treating muscle atrophy | Emerging Cross-Sectional Technologies | 43 | Active |
| US10337003B2 | Compositions for treating muscular dystrophy | Chemistry; Metallurgy | 41 | Active |
| US9217148B2 | Exon skipping compositions for treating muscular dystrophy | Emerging Cross-Sectional Technologies | 41 | Active |
| US8697858B2 | Antisense antiviral compound and method for treating influenza viral infection | Chemistry; Metallurgy | 39 | Active |
| US8785407B2 | Antisense antiviral agent and method for treating ssRNA viral infection | Human Necessities | 38 | Active |
| US8524676B2 | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds | Emerging Cross-Sectional Technologies | 38 | Active |
| US8501704B2 | Immunosuppression compound and treatment method | Chemistry; Metallurgy | 37 | Active |
| US10364431B2 | Compositions for treating muscular dystrophy | Chemistry; Metallurgy | 37 | Active |
| US8906872B2 | Antisense antiviral compound and method for treating ssRNA viral infection | Emerging Cross-Sectional Technologies | 36 | Active |
| US8592386B2 | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis | Chemistry; Metallurgy | 35 | Active |
| US8618270B2 | Oligonucleotide analog and method for treating flavivirus infections | Emerging Cross-Sectional Technologies | 35 | Active |
| US9161948B2 | Peptide oligonucleotide conjugates | Chemistry; Metallurgy | 35 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.